CA-DEBIOPHARM
9.1.2024 15:01:34 CET | Business Wire | Press release
MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner. The investment adds to a growing list of prominent digital health investors in Europe and the United States, including Nina Capital and Young Sohn, a co-founder of Veeva Systems. The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.
“We see significant synergies between MedaSystems and Debiopharm Innovation Fund. Our mutual dedication to building new approaches to pharmaceutical drug development and patient care will help bring promising pre-approval medicine to patients around the world, faster and more equitably. This funding supports our goal of making life-saving treatments more easily available to patients and physicians while advancing research and development of new therapies,” said Fiona Smythe, CEO of MedaSystems.
MedaSystems' SaaS platform facilitates the rapid processing of treatment inquiries and introduces new data capture capabilities, streamlining treatment for patients with unmet medical needs and aiding in collecting real-world data (RWD) for regulatory submissions. The platform is a vital link that ensures smooth collaboration among key partners in situations requiring pre-approval access. Physicians can swiftly manage patient requests and oversee the entire process in-app, working seamlessly with their teams and pharmacists. Pharmaceutical companies can integrate external partners like contract research organizations (CROs), guaranteeing effective communication, integrated services, and the quick shipment of treatment.
"Debiopharm Innovation Fund is committed to breaking down barriers in healthcare and promoting patient-centered solutions. Our investment in MedaSystems aligns perfectly with our dedication to innovation and the power of digital health technology in transforming patient outcomes. We believe their visionary approach to simplifying pre-approval access will play a key role in accelerating the delivery of life-saving treatments around the world. Together, we look forward to crafting a future where every patient has timely access to the most promising therapies." said Vincent Lepreux, Investment Principal at Debiopharm Innovation Fund.
About MedaSystems
MedaSystems is the leading developer of software that streamlines the handling of requests for experimental therapies from healthcare providers, supporting both Expanded Access and Post-Trial Access. MedaSystems' secure and GxP compliant application acts as a centralized environment, connecting physicians and pharmaceutical companies to facilitate global patient access to investigational therapies. By enabling the tracking and management of inquiries and data collection from these programs, MedaSystems transforms communications with clinicians into true partnerships, significantly reducing time and frustration for both parties involved.
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017, Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds. As of September 2023, Debiopharm Innovation Fund is expanding its footprint through a new Seed financing activity.
For more information, please visit www.debiopharm.com/innovation-fund/
To learn more about investment criteria visit https://www.debiopharm.com/innovation-fund/approach/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109101056/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme Raises SEK 75 Million to Advance Its Commercial Biomanufacturing Strategy23.9.2026 14:07:00 CEST | Press release
Enginzyme AB has closed a new equity round raising SEK 75 million. The round marks a key milestone in the company's shift from R&D to a commercially driven strategy. "With our growth strategy established, closing this new investment round was a priority for enginzyme," said Aymeric de Gantes, enginzyme's CEO. "We are also very excited to welcome new shareholders with complementary expertise, who will all contribute to our mission to deliver biomanufacturing solutions for the personal care, food, and pharmaceutical industries. Our technology enables lower cost in use for higher-quality ingredients, obtained through more sustainable manufacturing processes." Lotus One Investment Pte. Ltd. and Valquest Partners Europe are joining the company as new shareholders and members of the Board of Directors. Sofinnova Partners, Stiftelsen Industrifonden, Navigare Ventures AB and Almi Invest GreenTech were key participants, combined with several other new and existing shareholders. On Thursday, Sep
SLB Awarded Major Contract by OQEP for Integrated Facility Expansion in Oman23.9.2026 14:04:00 CEST | Press release
New award extends long-standing partnership and supports production growth through end-to-end project delivery and operations SLB (NYSE: SLB) has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922635677/en/ SLB has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. The expansion will increase the facility’s gross fluids handling capacity to 548,000 barrels
Datavault AI Announces Rights Offering to Shareholders23.9.2026 14:03:00 CEST | Press release
Rights offering to include both Common Unit and Preferred Unit subscription rightsMoody Capital Solutions, Inc. to act as dealer manager of a rights offering open to all shareholders of the company Datavault AI Inc. (Nasdaq: DVLT) (“Datavault AI” or the “Company”), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing and tokenization technologies, today announced that its board of directors (the “Board”) has approved a rights offering to holders of its common stock (“Common Stock”) and certain other Datavault AI securities. Moody Capital Solutions, Inc. (“Moody Capital”) will act as dealer manager for the rights offering. The Rights Offering to include investors in a process usually reserved exclusively for banks Under the rights offering, the Company will distribute, at no charge, transferable subscription rights to holders of record of Common Stock and certain other Company securities with a contractual right to participate in the distributio
Copeland Completes Acquisition of Dickson, Advancing Cold Chain Intelligence for Healthcare and Life Sciences23.9.2026 14:00:00 CEST | Press release
Combines monitoring, controls and software technologies to enable a more digitally connected cold chain Copeland, a global leader in compression technologies and controls solutions, today announced it has completed the acquisition of Dickson, a Chicago-based provider of environmental monitoring and compliance technology solutions for highly regulated life sciences and healthcare environments. Increasing regulatory demands across the pharmaceutical and life sciences cold chain require continuous visibility from production through final delivery. Together, Dickson’s cloud-native monitoring platform and Copeland’s controls, monitoring and enterprise software solutions will enable a more connected, intelligent and compliant cold chain. “We are pleased to welcome our new colleagues from Dickson into Copeland,” said Ross B. Shuster, CEO of Copeland. “The acquisition of Dickson further strengthens our ability to serve customers across every stage of the healthcare and life sciences cold chain
Sitetracker and 5x5 Break the Price Barrier for Portfolio-Scale Digital Twins and Asset Intelligence23.9.2026 12:11:00 CEST | Press release
Sitetracker and 5x5 partner to bring synthetic digital twins technology to the Wireless Infrastructure market. Sitetracker and 5x5 Technologies today introduced a data-to-twin workflow that gives wireless infrastructure owners a practical, affordable path to digitizing an entire tower portfolio. The Sitetracker platform now integrates 5x5 Synthetic Twin technology, providing scalable asset intelligence at a price up to 85% less than traditional site modeling methods. Synthetic Twins leverage Sitetracker’s leading tower portfolio and operational data to create interactive 3D models of towers, rooftops and ground compounds providing tower operators with a baseline of their portfolio that can be progressively enriched as the site conditions evolve. This data when combined with Scout, Sitetracker’s Agentic AI platform, opens the opportunity for digitized workflows and unparalleled understanding of the asset portfolio. Why it matters AI-driven data demand, more spectrum deployments, and den
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom